TY  -  
T1  - Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children 
SN  -  /  
UR  - http://hdl.handle.net/10138/203372 
T3  -  
A1  - Goncalves, Bronner P.; Pett, Helmi; Tiono, Alfred B.; Murry, Daryl; Sirima, Sodiomon B.; Niemi, Mikko; Bousema, Teun; Drakeley, Chris; ter Heine, Rob 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - Low-dose primaquine is recommended to prevent Plasmodium falciparum malaria transmission in areas threatened by artemisinin resistance and areas aiming for malaria elimination. Community treatment campaigns with artemisinin-based combination therapy in combination with the gametocytocidal primaquine dose target all age groups, but no studies thus far have assessed the pharmacokinetics of this gametocytocidal drug in African children. We recruited 40 children participating in a primaquine efficac... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - pharmacokinetics; primaquine; Plasmodium falciparum; CYP2D6; PLASMODIUM-VIVAX MALARIA; SINGLE-DOSE PRIMAQUINE; NEW-GUINEAN CHILDREN; ARTEMETHER-LUMEFANTRINE; DIHYDROARTEMISININ-PIPERAQUINE; UNCOMPLICATED MALARIA; FALCIPARUM-MALARIA; CONTROLLED-TRIAL; RADICAL CURE; DOUBLE-BLIND; 3111 Biomedicine; 3123 Gynaecology and paediatrics 
N1  -   
PP  -  
ER  -